We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0A4D market cap is 0. The company's latest EPS is USD -0.3797 and P/E is -4.27.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 15.76M | 36.08M |
| Operating Income | -26.73M | -29.55M | -37.79M | -62.08M | -14.52M |
| Net Income | -25.6M | -29.81M | -39.05M | -62.43M | -13.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 55.54M | 85.43M | 85.41M | 78.42M | 50.53M |
| Total Liabilities | 13.69M | 15.57M | 18.9M | 46.48M | 27.96M |
| Total Equity | 41.85M | 69.85M | 66.51M | 31.94M | 22.57M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -22.95M | -24.62M | -32.08M | -8.73M | -21.78M |
| Investing | -2.17M | -18.59M | 27.41M | 18.68M | -4.76M |
| Financing | 9.84M | 53.95M | 31.06M | -1.22M | -9.23M |
| Market Cap | 0 |
| Price to Earnings Ratio | -4.27 |
| Price to Sales Ratio | 1.58 |
| Price to Cash Ratio | 2.45 |
| Price to Book Ratio | 2.52 |
| Dividend Yield | - |
| Shares Outstanding | 35.12M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Equillium Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.equilliumbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
